---
layout: default
title: Activated Charcoal Aloe Citrullus Colocynthis Frui
parent: 僅模型預測 (L5)
nav_order: 168
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Aloe Citrullus Colocynthis Frui
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Botanical/Homeopathic Formula: Insufficient Data for Repurposing Evaluation

---

## One-Sentence Summary

This candidate is a complex eight-component mixture—Activated Charcoal, Aloe, Citrullus Colocynthis Fruit Pulp, Cupric Acetate, Ferrum Phosphoricum, Podophyllum, Potentilla Erecta Root, and Veratrum Album Root—which resembles a traditional or homeopathic combination product.
No original approved indications, no TxGNN predicted indications, and no market authorisations are on record.
As a result, **no evidence-based repurposing analysis can be completed at this stage**.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No approved indication on record |
| Predicted New Indication | No TxGNN prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — and none exists) |
| US/TW Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this candidate. The `predicted_indications` array in the Evidence Pack is empty, which means the knowledge-graph and deep-learning pipeline produced no scored disease targets for this mixture.

This is likely because the combination cannot be resolved to a single DrugBank ID (`drugbank_id: null`). TxGNN operates on individual, well-characterised molecular entities; a multi-component formula with heterogeneous ingredients—spanning an adsorbent (activated charcoal), botanical cathartics (Citrullus Colocynthis, Podophyllum), an Ayurvedic/homeopathic mineral (Ferrum Phosphoricum), a copper salt (Cupric Acetate), and a highly toxic alkaloid source (Veratrum Album)—cannot be mapped to a single node in the TxGNN knowledge graph.

Additionally, detailed mechanism of action (MOA) data is not available. Without either a prediction or an MOA anchor, mechanistic reasoning about potential new indications is not feasible.

---

## Safety Considerations

> Please refer to the package insert for safety information.

**Note for reviewers:** Several components in this formula carry significant independent safety concerns that should be investigated before any further evaluation:

- **Veratrum Album Root** contains veratrum alkaloids; even small doses can cause severe bradycardia, hypotension, and vomiting. It is classified as a highly toxic plant.
- **Podophyllum** contains podophyllotoxin, a cytotoxic and teratogenic compound; systemic absorption is hazardous.
- **Citrullus Colocynthis** is a potent cathartic with a narrow therapeutic window.
- **Cupric Acetate** is a heavy-metal salt; chronic exposure raises toxicity concerns.

These individual component risks must be comprehensively characterised before any repurposing direction is pursued.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack contains no TxGNN predictions, no approved indications, no safety profile, and no DrugBank linkage; there is no actionable evidence on which to base a repurposing recommendation. Several constituent ingredients also carry serious intrinsic toxicity concerns that require resolution before proceeding.

**To proceed, the following is needed:**

1. **Component decomposition**: Evaluate each of the eight ingredients individually through TxGNN to identify any ingredient-level repurposing signals.
2. **DrugBank mapping**: Obtain DrugBank IDs for each ingredient to enable knowledge-graph traversal and safety cross-referencing.
3. **MOA characterisation**: Retrieve mechanism of action data for each component from DrugBank, PharmGKB, or primary literature.
4. **Safety audit**: Conduct a full toxicology review—especially for Veratrum Album, Podophyllum, and Citrullus Colocynthis—before any human-use indication is considered.
5. **Regulatory history**: Determine whether this formula has ever received homeopathic or traditional medicine registration in any jurisdiction (e.g., HMPC in EU, OTC Homeopathic Monograph in the US, or TFDA Traditional Medicine Registry in Taiwan).
6. **Re-submission**: Once individual components are mapped, re-run the TxGNN pipeline on the primary active ingredient(s) and generate a new Evidence Pack.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

